Evercore ISI raised the firm’s price target on Stryker to $380 from $365 and keeps an Outperform rating on the shares. In MedTech, utilization remains positive into Q3 and the capex outlook into the next year remains “healthy,” says Evercore. In life science tools, bioprocess trends for are on track for improvement in the second half, but the debate is around the instrument outlook and China stimulus given the recent run in stocks in the space, the analyst tells investors in MedTech and Tools Q3 preview.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Stryker completes acquisition of Vertos Medical
- Wolfe starts Zimmer Biomet at Peer Perform, sees $115-$130 fair value
- Wolfe starts Stryker with an Outperform on leading orthopedics portfolio
- Stryker initiated with an Outperform at Wolfe Research
- Needham medtech & diagnostics analyst holds analyst/industry conference call